Programme

Investment in advanced scientific research and pharmaceutical manufacturing could create an important stimulus for the development of the Russian economy. Worldwide, pharmaceutical companies are investing around USD 140 billion in R&D annually. In order to join the list of countries considered to be attractive from an investment point of view by the pharmaceutical industry (the Biopharmaceutical Competitiveness and Investment Survey), the following criteria must be fulfilled: a stable economy, favourable legislation and tax regulations, a high concentration of intellectual resources, a good medical and pharmaceutical education system, and a highly productive workforce. To date, Russia has yet to be ranked among the top 20 in the survey. What measures can be taken to enable Russia to join the list of the most attractive countries for pharmaceutical investment? How can the priorities of Russia’s Scientific and Technological Development Strategy be realized in the areas of high-tech healthcare and pharmaceuticals? What barriers need to be overcome in state regulation of the pharmaceuticals market in order to expand access to medicines and increase investment attractiveness? How can more effective outcomes from scientific research in Russia be achieved?

Moderators
Guzel Ulumbekova , President of the Board, Association of Medical Societies for Quality of Medical Care and Medical Education; Head, Higher School of Healthcare Organization and Management
Vladimir Shipkov , Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)

Guzel Ulumbekova

President of the Board, Association of Medical Societies for Quality of Medical Care and Medical Education; Head, Higher School of Healthcare Organization and Management

Head of the Higher School of Healthcare Organization and Management, Chairman of the Board of the Association of Medical Communities for the Quality of Medical Care and Medical Education. Chairman of the Commission on Continuing Education of the National Medical Chamber, member of the Coordinating Council of the Ministry of Healthcare of Russia for Development of Continuing Medical and Pharmaceutical Education, member of the Board and Executive Secretary of the Russian Society for Healthcare Organization and Public Health. Since 2003, she has been heavily involved in expert activities on healthcare organization at the Civic Chamber and the Chamber of Commerce and Industry of the Russian Federation, the State Duma Committee on Healthcare, the Strategic Research Centre of the Ministry of Economic Development of the Russian Federation, the WHO Council for Evidence-Based Medicine, etc. Guzel Ulumbekova is the author of the books Russia’s Healthcare. What Needs to Be Done (2010) and Russia’s Healthcare. What Needs to Be Done-2 (2015) and a textbook for medical schools Public Health and Healthcare (2011); she is a contributor to and a member of the editorial board of the national guide Public Health and Healthcare (2013).

Vladimir Shipkov

Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)

Education: 1974 – Military Institute of Foreign Languages. 1991 – Russian State University for the Humanities. Professional activities: Mr. Shipkov began his career in law enforcement. From 1998 to 2000, he was a board member of the State Customs Committee of the Russian Fed-eration. In 1999, he was appointed director of the Personnel Department and a board member of the State Customs Committee and then worked in the State Duma administrative office. From 2000 to 2004, he served as director of pharmaceutical inspections at the Ministry of Healthcare. In 2004, he was appointed deputy director of the Federal Service for Intellectual Property, Patents and Trademarks (Rospatent). He also took part in the work of a medicine licensing commission of the Federal Service for the Supervision of Public Health and Social Development. Since 2007, he has been the executive director of AIPM.

Panellists
Marwan Akar , General Director, MSD Russia
Sergei Alyabiev , Partner, McKinsey & Company
Anatoly Artamonov , Governor of Kaluga Region
Elena Bushberg , General Director, Veropharm
Vasily Ignatiev , General Director, R-Pharm JSC
Elena Kartasheva , General Director, Abbott Russia
Elena Maksimkina , Director of Medicine Assistance and Medical Products Revision Regulation Department, Ministry of Healthcare of the Russian Federation
Eyal Mishani , Head, Cyclotron Radiochemistry Unit, Hadassah Hebrew University Hospital
Dmitry Morozov , President, BIOCAD
Mikhail Murashko , Head, Federal Service on Surveillance in Healthcare
Igor Narkevich , Rector, St. Petersburg State Chemical-Pharmaceutical Academy
Ludmila Ogorodova , Deputy Minister of Education and Science of the Russian Federation
Gisela Payeras Bailly , Director for Government Affairs in Emerging Markets, GSK (GlaxoSmithKline); Chair, Emerging Markets Working Group, The European Federation of Pharmaceutical Industries and Associations (EFPIA)
Irina Panarina , General Manager, Russia and Eurasia, AstraZeneca
Nikolaos Tripodis , Managing Director, Novartis Pharmaceuticals in Russia
Dmitry Khalilov , Partner, Head of the Group for the Provision of Services to Enterprises of the Consumer Goods Sector, CIS, EY
Niels Hessmann , General Director, Bayer; General Representative, Russia and CIS, Bayer
Vladislav Shestakov , Director, State Institute of Drugs and Good Practices

Marwan Akar

General Director, MSD Russia

Г-н Акар начал работу в MSD в качестве инженера-технолога производства. По мере развития карьеры он занимал разные должности с возрастающей сферой ответственности, руководил проектами по трансферу технологий производства вакцин и других лекарственных препаратов, способствовал наращиванию производственных мощностей MSD и компаний-партнеров по всему миру. В 2008 году г-н Акар был назначен на пост руководителя операций производственного подразделения MSD в регионах «Восточная Европа, Ближний Восток и Африка» и «Европа и Канада». В этой роли он поддерживал стратегические проекты по развитию бизнеса, а также отвечал за партнерства с локальными производителями, в том числе в России. Г-н Акар получил диплом магистра в Мэрилэндском университете (США) по специальности «Химик-технолог». Он также закончил обучение по программе МВА (Магистр делового администрирования) в Имперском колледже Лондона.

Anatoly Artamonov

Governor of Kaluga Region

Born in 1952 Krasnoye village, the Hvastovichi district of the Kaluga Region. In 1974 graduated from Moscow Agricultural Production Engineering Institute named after V.P. Goryachkin. On graduating the institute came to Hvastovici district of the Kaluga Region, where worked as a state farm “Hvastvichesky" repair shops’ chief. Since 1975 - Chief Engineer of the state farm "Shahtovsky" in Mosalsk district. In 1978 was appointed "Gruzdovsky" state farm Director. In 1985 - Chief of the Regional Agricultural Department, and a few months later was elected First Secretary of CPSU Mosalsk district committee. In 1991 was appointed Obninsk construction and industrial joint stock company CEO. Since November 1996 – Vice Governor of the Kaluga Region. November 12, 2000 was elected Governor of the Kaluga Region. March 14, 2004 was elected Governor of the Kaluga Region for the second time. July 22, 2005 according to the new order of forming executive powers of governmental authorities the President of the Russian Federation V.V. Putin introduced A.D. Artamonov’s candidature for considering of the Kaluga Region Legislative Assembly to appoint him the authority of the Kaluga Region Governor. July 26, 2005 the Kaluga Region Legislative Assembly deputies made up their minds to appoint A.D.Artamonov the authority of the Kaluga Region Governor for a five year term on a special session. July 26, 2010 the Governor came into office for another term on.

Elena Bushberg

General Director, Veropharm

Elena Bushberg leads Veropharm, which became part of Abbott in 2014, since February 2015. Prior to being named in this role, Elena was Director of Cardiology & Neurology for Abbott’s Established Pharmaceuticals business in Russia. Before joining Abbott, Elena held different positions in finance, marketing and business operations at Schering-Plough and MSD. Elena obtained a degree in philology from Moscow State Linguistic University as well as an Executive MBA degree from the Duke University, USA

Vasily Ignatiev

General Director, R-Pharm JSC

Was born in 1968 in Moscow. In 1985 graduated from secondary school No.44 of Moscow with gold medal and entered the 1st medical faculty of the 1st Moscow Medical Institute (afterwards - Moscow Medical Academy) named after Sechenov. In 1987, having finished the 2nd course, was called to arms by the Military Forces. After demobilization in 1989 continued studying in MMA – first at the 1st medical faculty and from the 4th course at the Faculty of scientific and scientific-pedagogic personnel training, from which graduated with honors in 1993. While studying from June to October 1992, did traineeship in the University of Columbia (the city of New York, USA) within the framework of interuniversity program of students exchange. In 1993-1995 did postgraduate studies at the chair of clinical pharmacology of MMA named after Sechenov. In 1995-2002 occupied the positions of Product Manager, Marketing Manager, Marketing Director at the representative office of the international pharmaceutical company “Bristol-Myers Squibb”. In 2002-2006 worked in the position of Marketing and Sales Director in the representative office on the international pharmaceutical company “Astra-Zeneka”. Simultaneously from 2001 to 2007 pluralistically worked as research officer in the laboratory of historic and scientific researches of SPA “Medical Encyclopedia” of RAMS, in December of 2004 defended dissertation to seek the scientific degree of the medical sciences candidate. In 2006-2007 worked as Marketing and Sales Director in the Russian-Dutch tire holding of OJSC “Amtel-Fredestein”. Since 2008 work in the first rate Russian producer and distributor of pharmaceuticals “R-Pharm” as Chief Executive Officer. Married, six children.

Elena Kartasheva

General Director, Abbott Russia

Elena Kartasheva joined Abbott Russia in July 2014 as General Manager for the company. In her role, Elena is focused on expanding Abbott’s Established Pharmaceuticals business in Russia including further development of the pharmaceutical product portfolio. Prior to joining Abbott, Elena headed Meda Pharmaceuticals in Russia for three years managing a wide portfolio of products across multiple market segments including prescription medicines, hospital and OTC. Previously she worked for Sanofi, Novartis Group and Pliva (TEVA) in a variety of sales, marketing and business unit head roles. Elena holds a PhD in Oncology as well as a Masters in Medicine from the Sechenov Moscow State Medical University, Department of General Medicine.

Eyal Mishani

Head, Cyclotron Radiochemistry Unit, Hadassah Hebrew University Hospital

Born in Israel in 1963, married with two children. In 1990, I received my Bachelor’s degree in Chemistry from Tel Aviv University With Distinction. Subsequently, I started direct courses towards Ph.D. studies in the field of Organic Fluorine Chemistry. In 1994, I received my Ph.D. degree With Distinction from Tel Aviv University. From 1994-1996, I completed my post-doctoral fellowship at Washington University, St. Louis, MO, in the field of PET molecular imaging. During my postdoctoral fellowship, I designed the PET/Radiochemistry Laboratory at Hadassah/Hebrew University Hospital in Israel. Beginning of 1997, I returned to Israel to establish the first PET Cyclotron facility in Israel in which I presently serve as Head of the Unit. Upon my return to Israel, I pioneered the production and distribution of FDG which completely transformed the clinical diagnostic approach in this country. In conjunction with the Health Ministry, I established the guidelines for FDG production. In 2012, I was appointed as a full Professor at Hadassah/Hebrew University Hospital. I am a member of the editorial board of Nuclear Medicine and Biology (the official journal of the Society of Radiopharmaceutical Sciences) and I serve as the International Associate Editor of Molecular Imaging and Biology (the official journal of the Society of Molecular Imaging). Recently, I served as the director at large of the International Society of Radiopharmaceutical Sciences (2011-2013). Throughout the ensuing years, I served as reviewer of several journals such as Journal of Medicinal Chemistry, Journal of Nuclear Medicine, Journal of Labeled Compounds and Radiopharmaceuticals, Applied Radiation and Isotopes, etc. My main research aim is to develop molecular imaging methodologies to explore the in–vivo mechanism of various biochemical processes under normal and pathological conditions and translate them into imaging of diseases. In this context, I have pioneered several basic and comprehensive research projects encompassing various fields of nuclear medicine molecular imaging. I have published over 85 scientific papers in peer-reviewed journals and have five patents in the field of imaging protein tyrosine kinases and AR in cancer. Most importantly, the research on imaging EGFR in cancer was a pioneering endeavor from which several research reports have emanated by others throughout the years. In fact, several clinical trials have recently been initiated in Europe and the U.S. principally based on our initial work. Based on our research, I have been invited by reputed journals to contribute three reviews in this field. During the past 12 years, I have served as mentor to seven Ph.D. and to four M.Sc. students in the field of molecular imaging and I have formulated a special course in this particular field at the School of Pharmacy of the Hebrew University. In 2010, I completed the installation of a second Cyclotron and a microPET/CT (the first in Israel) at Hadassah Hospital. In mid-2014, I was appointed to be the Head of the R&D division at Hadassah, the General Director of the Research Fund of the Hadassah Medical Organization (RFHMO) and a board member of Hadassit the technology transfer company of Hadassah. I established the research fund as an independent legal entity and today there are 200 research employees with an income for research projects totaling almost 100M shekels annually.

Dmitry Morozov

President, BIOCAD

Date of birth: February 1, 1965 Place of birth: Moscow Marital status: Married, with three children Dmitry Morozov is a member of the Council for Development of the Pharmaceutical and Medical Industry attached to the Government of the Russian Federation. He is on the list of the Top 500 reserve management executives under the auspices of the President of the Russian Federation.Dmitry Morozov graduated from the Radio Technology Department of the State Academy of Consumer Services in Moscow. 1997–1998: Studied at the Plekhanov Russian Academy of Economy in Moscow, Department of Finance and Credit. Earned a diploma in Economics. 1998: Successfully completed an MBA programme at the MIRBIS Moscow International Higher School of Business and obtained an MBA in Management. 2004: Studied at the Keio Business School in Japan under a presidential programme. 1993–2002: Vice Chairman of the Management Board, CentroCredit Bank. 2001: Founded CJSC Biocad; currently serves as its President. Biocad manufactures ready-made medicines, pharmaceutical substances and genetic engineering products.

Ludmila Ogorodova

Deputy Minister of Education and Science of the Russian Federation

Born July 30, 1957 in Anzhero-Sudzhensk, Kemerovo Region. 1980: graduated from Tomsk State Medical Institute with a degree in paediatrics. 1996–1998: lectured in the 3rd children’s diseases department of the Siberian State Medical University. 1997: appointed Professor at the same university. 1998: appointed Dean of Science at the Siberian State Medical University. Since 1998: head of the paediatrics department. 2003–2011: Dean of Science at the Siberian State Medical University of the Russian Ministry of Healthcare (in 2005, renamed the Siberian State Medical University, Federal Agency for Health and Social Development). 2000: received the highest qualification of medical proficiency in immunology, in 2001 in pediatrics. 2007: elected member of the Russian Academy of Medical Sciences, awarded the title of Honoured Scholar of Russian Federation. Presides over the Medicine of the Future technological platform in Tomsk. December 2011: elected to the State Duma from the Tomsk Region. Since 2013 acts as deputy minister of Education and Science. Married. Has a daughter.

Gisela Payeras Bailly

Director for Government Affairs in Emerging Markets, GSK (GlaxoSmithKline); Chair, Emerging Markets Working Group, The European Federation of Pharmaceutical Industries and Associations (EFPIA)

Gisela Payeras Bailly is Government Affairs Director for Emerging Markets at GlaxoSmithKline (GSK), Head of Government Affairs for the MENA / CIS region and member of the regional leadership team. She is based in Brussels, where she also leads on relations with EU stakeholders for international markets. Gisela is a member of the European Federation of Pharmaceutical Industries (EFPIA) International Board Sponsor Committee and is currently the Chair of EFPIA’s Growth Markets working group. Gisela has worked in the pharmaceutical industry for over 17 years, in GSK and previously for EFPIA, where she had responsibilities in economic and international affairs. She has also worked for Banco Santander Central Hispano, the Spanish Confederation of Industries (CEOE) and the European Commission. Gisela has a Degree in Economic Sciences & Business from Universitat Pompeu Fabra (Barcelona, Spain) and a Master of Arts in Advance European Economic Studies from the College of Europe (Bruges, Belgium). Gisela is married with two children.

Irina Panarina

General Manager, Russia and Eurasia, AstraZeneca

Since May 2017 Irina Panarina has been appointed to the position of General Manager of AstraZeneca, Russia and Eurasia. Irina is responsible for AstraZeneca business in Russia & Eurasia Area and she leads AstraZeneca Russia. Irina Panarina has worked for AstraZeneca since 2009. In October 2015 Irina joined the Russian team as Cardiovascular and Metabolic Disease Business Unit Head. Before coming to Russia, Irina Panarina held the position of General Manager at AstraZeneca Ukraine. Prior to joining AstraZeneca Irina held regional roles at GSK Pharma headquarters in London, UK. Irina Panarina has work experience in marketing, product portfolio management, people development. Irina Panarina has degrees from Newcastle University & South Bank University. She also holds MBA degree from INSEAD Business School.

Nikolaos Tripodis

Managing Director, Novartis Pharmaceuticals in Russia

Dr. Nikolaos Tripodis is CPO Head, Russia, effective September 1, 2016. Before joining Novartis Russia Dr. Tripodis was for more than 2 years the President and Managing Director of Novartis Healthcare Philippines Inc. During this period, he oversaw and directed the Palawan Access to Medicines program with the Gates Foundation, and the leprosy detection LEARNS program (with Novartis Foundation). Dr. Tripodis was also Vice President of the Pharmaceutical and Healthcare Association of the Philippines (PHAP). Dr. Tripodis joined Novartis in 2011 as Director Corporate Strategic Planning at Novartis International AG in its headquarters in Basel, Switzerland. Among others, he led projects that aim to define the key strategic actions that Novartis needs to undertake to remain competitive globally in next decade, create a leading presence in the African continent as well as re-designing the Novartis Social Business Ventures Group. Before joining Novartis Dr. Tripodis for 3 years has held commercial roles in AstraZeneca and has worked for 5 years with the Boston Consulting Group (BCG) across Europe, the Middle East and Asia. Prior to BCG, he was involved in genomics research. He was a King’s Fellow at the Genomics Laboratory at King’s College, GKT Medical School, University of London as well as a Post-doctoral Fellow at the Netherlands Cancer Institute in Amsterdam. Dr. Tripodis completed his PhD at King’s College, University of London in the United Kingdom and Bachelor of Science in Biology at the University of Athens, Greece. He received additional training in bioinformatics at MIT and microsurgery at Utrecht University. He is a recipient of the American Association for Cancer Research AFLAC/AACR Scholar Award.

Dmitry Khalilov

Partner, Head of the Group for the Provision of Services to Enterprises of the Consumer Goods Sector, CIS, EY

Over 20 years of experience in providing tax advisory services to pharmaceutical and health companies; experience in managing advisory engagements for international and Russian companies in the areas of Russian and international tax planning and tax optimization, structuring of operations, cross-border and domestic transactions and other ongoing tax issues, as well as launching an IPO on international financial markets; major clients include Takeda (Nycomed), Novo Nordisk, Abbott Laboratories, Astellas Pharma, AstraZeneca, Berlin-Chemie/Menarini, Teva, Johnson & Johnson, Pfizer, UCB, Merck, Pharmstandard, Novartis.Member of an organizational committee of the interactive discussion platform Viable Healthcare, established by The Russian Presidential Academy of National Economy and Public Administration (RANEPA) and The Business Administration of the President of the Russian Federation. Moscow State Academy of Law, degree in Tax Law; Moscow institute of State and Corporate Management, Bachelor’s degree in Economics

Niels Hessmann

General Director, Bayer; General Representative, Russia and CIS, Bayer

Niels Hessmann is the Managing Director of Bayer JSC and Senior Bayer Representative in Russia and CIS since March 1, 2015. Niels Hessmann was born in Belgium and studied applied economic sciences at the University of Antwerp, Belgium. He began his career as a Market Research Manager in Schering (now Bayer) in Belgium in 1992. In 1996, he headed the Marketing and Sales Department of Schering Romania and Moldova. In 1999, he became the Managing Director of Schering Kazakhstan and was responsible for the company development in Central Asia. In 2001, he was appointed the Managing Director of Schering Greece. In 2007, he headed Bayer Netherlands and was Bayer Healthcare Representative. During that period, Mr. Hessmann was also responsible for merging Bayer and Schering. From November 2011 to February 2015, he was the Managing Director and Country Division Head Bayer HealthCare in South-Korea.

Vladislav Shestakov

Director, State Institute of Drugs and Good Practices

Shestakov, Vladislav (born on November 27, 1969, in Salekhard, USSR) is a Director of State Institute of Drugs and Good Practices, Deputy Director of Russian State GMP-Inspectorate. Before being appointed as a Director of the Institute served as Chairman of the Pharmacy and Biotechnology branch offices of All Russia Public Organization “Business Russia”. Honorary chemist, a certified inspector and GMP auditor. Russian State GMP-Inspectorate Deputy Head and Head of the GP Committee of the Pharmacy vocational qualifications Council of the National Pharmaceutical Chamber. Since 1997 has been working in the field of healthcare and pharmacy. Biography Born on November 27, 1969 in Salekhard, Yamalo-Nenets Autonomous area, USSR. In 1987 he entered the Tyumen State Medical Institute, in 1989 he continued his studies at the Smolensk State Medical Academy. He graduated from the State University of Management (2005), specialty – “State and municipal management”. In 2008 he graduated from the Academy of Labor and Social Relations, “Business Administration”. In 2016 he got a vocational retraining diploma of the Moscow Institute of Physics and Technology (MIPT), "GMP and drugs quality control - theory and practice of GMP-inspection / audit." 2000 - Deputy Director-General, Irbitsky Chemical and Pharmaceutical Plant. 2001-2001 - Vice-president, Rosmedprom. 2002-2003 - Head of commercial department, Hemofarm, Moscow office. 2004-2005 - Deputy Director-General, Makiz-Pharma. 2005 - General Director, Skopinsky Pharmaceutical Plant. 2007 – GR Director, Union of Professional Pharmaceutical Organizations. 2008 – President, Epidbiomed Group of Companies. 2009 - Business Development Director, Binnopharm. 2011-2012 – Counselor to the Director-General, Usolie-Sibirskiy Khimfarmzavod. 2012-2013 – Deputy Director-General, Nanolek. On November 27, 2013, Shestakov was appointed as Director of State Institute of Drugs and Good Practices. Since 2003, he has been a regular lecturer of educational programs for professional development in the field of managing the commercial and government organizations’ activities, as well as specialized programs in pharmaceuticals and pharmaceutical production. He has the certificate of the international inspector of WHO on good manufacturing practice. Awards • The title of “Honorary Chemist” • Certificate of Honor from the Minister of Industry and Trade of the Russian Federation “For achieved progress at work”.